跳至主要内容
临床试验/NCT04901260
NCT04901260已完成不适用

AMAZE™ Asthma Implementation Quality Improvement Study

AstraZeneca1 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2020年11月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
117
试验地点
1
主要终点
Clinician Dashboard Usage

研究概览

简要总结

The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.

详细描述

AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of patients throughout their patient care journey. AMAZE™ integrates multiple systems, including a patient mobile application where patients can enter daily symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials. Implementation of AMAZE™ within clinical practice has not yet been evaluated. The results from this study will be used to inform any changes or modifications that need to be made to the technology platform, its implementation process, and explore impact on clinical outcomes.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • >18 years of age at the time of enrollment
  • Clinically confirmed diagnosis of asthma
  • Access to a smartphone with internet access with the following requirements: iOS (Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating System 8.0 or newer)
  • Able to understand and speak English sufficiently to be able to use the AMAZE™ patient App
  • Willingness to participate in a telephone interview and be audio-recorded
  • Consenting to participate in the study

排除标准

  • Current diagnosis of active chronic obstructive pulmonary disease (COPD) or any pulmonary diagnosis other than asthma;
  • Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, or insufficient knowledge of the English language that, in the opinion of the investigator, would interfere with his or her ability to agree to participate and/or complete the ACT™

结局指标

主要结局

Clinician Dashboard Usage

时间窗: Up to 6 months

Clinician dashboard usage will be measured as the mean number of days per week/month that the clinical site staff accessed the AMAZE™ dashboard over the 6-month period.

Symptoms and Triggers

时间窗: Up to 6 months

Frequency of symptoms and frequency of triggers (for those that reported symptoms) reported on the app will be described weekly during Months 1, and then per month from Month 1 through Month 6 pending availability of data after Month 1.

Patient App Usage

时间窗: Up to 6 months

Patient app usage will be measured as the number of days the patient engages (i.e., completes daily log, sends a message) with the app at least once a day during the study period.

Self-Reported Rescue Medication usage

时间窗: Up to 6 months

The number of times per month a patient used rescue medication as well as visited the emergency room or urgent care as reported on the app will be described from Month 1 through Month 6.

Daily Asthma status

时间窗: Up to 6 months

Patient daily asthma status (bad, okay, good) reported on the app will be described weekly during Month 1, and then per month from Month 1 through Month 6 pending availability of data after Month 1.

次要结局

  • ER visits and Hospitalization avoidance(Up to 6 months)
  • Patient Perception of Usability and Design of Mobile app(Up to 6 months)
  • Clinical Staff Perception of Usability and Design of Dashboard(Up to 6 months)
  • Evaluate ease of implementation of AMAZE™ in clinical setting(Up to 6 months)
  • Evaluate Perceived Benefit of AMAZE™ in clinical setting(Up to 6 months)
  • Impact of AMAZE™ on patient visits(Up to 6 months)
  • Evaluate Perceived Disadvantages of AMAZE™ in clinical setting(Up to 6 months)
  • Evaluate patient satisfaction with healthcare experience(Up to 6 months)
  • Patient Perception of Appointment Discussions and Taking Part in Asthma Decisions(Up to 6 months)
  • Evaluate impact of AMAZE™ on managing patients(Up to 6 months)
  • Evaluate patient satisfaction with app(Up to 6 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验